European CHMP recommends license extension of dapagliflozin (Forxiga) for treatment of chronic kidney disease
The license extension is for the treatment of chronic kidney disease in adults.
Source:
European Medicines Agency
The license extension is for the treatment of chronic kidney disease in adults.
European Medicines Agency
SPS commentary:
NICE is due to appraise the clinical and cost effectiveness of dapagliflozin within its marketing authorisation for treating chronic kidney disease.